Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3022449 | 0.94 | LMNA (0.46) | LMNAGAAADRB2ADRB1ADRB3 | |
| SCHEMBL3028686 | 0.86 | ADRB2 (0.45) | LMNAGAAADRB2ADRB1ADRB3 | |
| SCHEMBL10260646 | 0.83 | LMNA (0.47) | LMNAGAAADRB2ADRB1ADRB3 | |
| SCHEMBL2840247 | 0.81 | ADRB2 (0.49) | LMNAGAAADRB2ADRB1ADRB3 | |
| SCHEMBL10291709 | 0.81 | LMNA (0.39) | LMNAADRB2ADRB1ADRB3SMN1; SMN2 | |
| SCHEMBL11948444 | 0.77 | LMNA (0.43) | LMNAGAAADRB2ADRB1ADRB3 | |
| SCHEMBL3036232 | 0.75 | LMNA (0.52) | LMNAGAATSHRPOLBHTT | |
| SCHEMBL10267568 | 0.75 | LMNA (0.42) | LMNAGAAADRB2ADRB1ADRB3 | |
| SCHEMBL3042954 | 0.75 | SMN1; SMN2 (0.39) | LMNAGAAADRB2TSHRPOLB | |
| SCHEMBL3040492 | 0.75 | ATM (0.41) | LMNAGAAADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211923-B2 | Substituted arylsulfonylaminomethylphosphonic acid derivatives, their preparation and their use in the treatment of type I and II diabetes mellitus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-03 | — | — | US | disclosed |
| US-8211923-B2 | Substituted arylsulfonylaminomethylphosphonic acid derivatives, their preparation and their use in the treatment of type I and II diabetes mellitus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-03 | — | — | US | disclosed |
| US-20100210595-A1 | SUBSTITUTED ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF TYPE I AND II DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210595-A1 | SUBSTITUTED ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF TYPE I AND II DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210595-A1 | SUBSTITUTED ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF TYPE I AND II DIABETES MELLITUS | G6PC1, PYGL, PPP1CA | LMNA 732/4885GAA 177/4885ADRB2 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.